Accera Feeds the Brain to Fight Alzheimer's Disease
BioWorld Insight Contributing Writer
While most of the industry focuses on beta amyloid and tau as targets for Alzheimer's disease, Accera Inc. has turned its attention to a deficit in the ability of Alzheimer's patients' brain cells to metabolize glucose.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST